Turn Therapeutics Discloses Going Concern Doubt, Secures $25M Loan, and Faces Significant Dilution Risk
TTRX sits 25% above its 52-week low of $2.57 on light trading volume (0.4× avg).
Summary
Turn Therapeutics Inc. filed its annual report, disclosing substantial doubt about its ability to continue as a going concern due to significant losses and cash burn. The company secured a new $25 million loan facility and has an existing $85 million equity purchase agreement to address its capital needs, but faces substantial potential dilution.
Key Events · Financing and Capital Events · TTRX
-
Substantial Doubt About Going Concern
The company's consolidated financial statements express substantial doubt about its ability to continue as a going concern due to insufficient capital to fund its drug development plans and expected cash needs beyond Q3 2026.
-
Secured New $25 Million Loan Facility
On March 23, 2026, the company entered into a Loan and Security Agreement with Avenue Capital for up to $25 million, with an initial $7 million funded on March 24, 2026. The loan bears interest at the greater of (5.50% + prime rate) or 12.25% and is secured by all company assets. The lender also received 342,857 shares at no cost and has a dilutive conversion option for up to $2.0 million of principal at 80% of the trading price.
-
Ongoing $85 Million Equity Purchase Agreement
An existing agreement with GEM allows the company to sell up to $85 million in common stock at 90% of the average daily closing price. As of December 31, 2025, $4.07 million has been raised, and a warrant for 1,192,207 shares (4% of fully diluted equity) was issued to GEM at an exercise price of $5.03.
-
Significant Potential Dilution
The company has 500,000,000 authorized common shares and 29,788,040 shares outstanding as of March 30, 2026. If all authorized shares were issued, dilution would be 1578.5%.
Analysis · TTRX · Life Sciences
Turn Therapeutics Inc.'s annual report reveals substantial doubt about its ability to continue as a going concern, driven by increasing net losses and significant cash burn. The company has secured a new $25 million loan facility from Avenue Capital, with an initial $7 million funded, but this debt bears a high interest rate and is secured by all company assets. Additionally, the lender holds a dilutive conversion option for up to $2.0 million of the principal into common stock at 80% of the trading price. The existing $85 million equity purchase agreement with GEM, under which $4.07 million has been raised, also involves sales at a discount to market price and includes a warrant for 1.19 million shares. With over 470 million authorized but unissued shares, the company faces potential dilution exceeding 1500% if all authorized shares were issued. While these financing efforts provide a temporary capital runway, they underscore the company's precarious financial position and the high cost of capital, posing a significant risk to existing shareholders.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TTRX was trading at $3.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $94.2M. The 52-week trading range was $2.57 to $26.50. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.